Welcome to our dedicated page for Enovis news (Ticker: ENOV), a resource for investors and traders seeking the latest updates and insights on Enovis stock.
Enovis Corporation reports recurring developments as a medical technology company focused on reconstructive surgery, rehabilitation, pain management, physical therapy and musculoskeletal care. Company news centers on financial results, guidance, organic sales trends and segment performance in Reconstructive and Prevention & Recovery, including updates tied to new product introductions and end-market conditions.
Enovis announcements also include conference participation and investor presentation activity, with business commentary on clinically differentiated solutions intended to enhance patient outcomes, restore motion and support surgeons, clinicians and other healthcare professionals.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Enovis Corporation (NYSE: ENOV) will host an investor conference call and live webcast on May 4, 2023, at 8:30 a.m. Eastern Time to discuss its first quarter 2023 financial results. An earnings press release will be issued earlier that morning, with a presentation accessible on the Enovis website in the 'Investors' section.
Participants can join the live webcast through the company's website. For those wishing to join the call, U.S. callers can dial (833) 630-1956, while international participants can call (412) 317-1837. A replay of the call will also be available on the website later the same day.
Enovis focuses on innovating medical technology solutions that improve patient outcomes and transform workflows in orthopedics.
Enovis Corporation (NYSE: ENOV) has announced its acquisition of Novastep, a leader in Minimally Invasive Surgery (MIS) for foot and ankle solutions, for approximately $20 million in annual revenues. This strategic move is aimed at enhancing Enovis' portfolio and global presence in the $3 billion foot and ankle market. The acquisition includes Novastep's innovative Pecaplasty bunion system, which offers superior patient outcomes by promoting quicker recovery and reduced discomfort. The transaction, subject to regulatory approval, is expected to finalize in Q2 2023, further solidifying Enovis' commitment to improving patient care and driving business growth.